Specifcity may be overrated in cancer immunotherapy: Getting to know the nonspecifc side of memory T cells

OncoImmunology

Volumn 1, Issue 7, 2012, Pages 1208-1210

  Sckisel, Gail D ^a   Murphy, William J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antigen non specific T cells; Bystander CD8 T cells; Cancer immunotherapy; Cytokine induced killer cells; LAK cells; NKG2D

Indexed keywords

IMIQUIMOD; INTERLEUKIN 2 RECEPTOR ALPHA; IPILIMUMAB; NATURAL KILLER CELL RECEPTOR NKG2D; OVALBUMIN; SIPULEUCEL T; T LYMPHOCYTE RECEPTOR;

ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BYSTANDER EFFECT; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DRUG APPROVAL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; INNATE IMMUNITY; LYMPHOCYTE FUNCTION; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MEMORY T LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

EID: 84886944954     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.20779     Document Type: Article

References (10)

1. Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo N P. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006; 6:383-93; PMID:16622476; http://dx.doi.org/10.1038/nri1842.
2. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010; 10:317-27; PMID:20414205; http://dx.doi.org/10.1038/nri2744.
3. Tietze JK, Wilkins DE, Sckisel GD, Bouchlaka MN, Alderson KL, Weiss JM, et al. Delineation of antigen-specific and antigen-nonspecific CD8(+) memory T-cell responses after cytokine-based cancer immuno-therapy. Blood 2012; 119:3073-83; PMID:22251483; http://dx.doi.org/10.1182/blood-2011-07-369736.
4. Naylor K, Li G, Vallejo AN, Lee WW, Koetz K, Bryl E, et al. The influence of age on T cell generation and TCR diversity. J Immunol 2005; 174:7446-52; PMID:15905594.
5. Schwab R, Szabo P, Manavalan JS, Weksler ME, Posnett DN, Pannetier C, et al. Expanded CD4+ and CD8+ T cell clones in elderly humans. J Immunol 1997; 158:4493-9; PMID:9127016.
6. Clark RA, Chong B, Mirchandani N, Brinster NK, Yamanaka K, Dowgiert RK, et al. The vast majority of CLA+ T cells are resident in normal skin. J Immunol 2006; 176:4431-9; PMID:16547281.
7. Ehl S, Hombach J, Aichele P, Hengartner H, Zinkernagel RM. Bystander activation of cytotoxic T cells: studies on the mechanism and evaluation of in vivo significance in a transgenic mouse model. J Exp Med 1997; 185:1241-51; PMID:9104811; http://dx.doi.org/10.1084/jem.185.7.1241.
8. Meresse B, Chen Z, Ciszewski C, Tretiakova M, Bhagat G, Krausz TN, et al. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 2004; 21:357-66; PMID:15357947; http://dx.doi.org/10.1016/j.immuni.2004.06.020.
9. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3:991-8; PMID:12407406; http://dx.doi.org/10.1038/ni1102-991.
10. Zhang L, Gajewski TF, Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 2009; 114:1545-52; PMID:19417208; http://dx.doi.org/10.1182/blood-2009-03-206672.